
Currently out of the existing stock ratings of Kevin Fischbeck, 37 are a SELL (15.29%), 130 are a BUY (53.72%), 75 are a HOLD (30.99%).
Analyst Kevin Fischbeck, currently employed at BAML, has had 69.54% of price targets met with an average potential upside of 24.65%, reached in 267 days on average.
Kevin Fischbeck has documented 472 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ARDT, Ardent Health Partners.
Analyst best performing recommendations are on CLOV (CLOVER HEALTH INVESTMENTS CORP).
The best stock recommendation documented was for HUM (HUMANA) on 6/24/2026. The price target of $380 was fulfilled within 2 days with a profit of $19.21 (5.32%), with a performance score of 26.62.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 09-May-2021
$170
$59.7 (54.13%)
$146
4 days ago
(12-Nov-2026)
Buy Since 19-Oct-2023
$145
$34.7 (31.46%)
$140
6 days ago
(10-Nov-2026)
4/11 (36.36%)
$30.19 (26.30%)
131
Hold Since 11-Jun-2023
$105
$-5.3 (-4.81%)
$125
12 days ago
(04-Nov-2026)
3/8 (37.5%)
$-8.77 (-7.71%)
7
Hold Since 16-Oct-2025
$125
$14.7 (13.33%)
$86
2 months 2 days ago
(14-Sep-2026)
5/9 (55.56%)
$32.88 (35.69%)
56
Sell Since 23-Aug-2026
$85
$-25.3 (-22.94%)
$150
2 months 24 days ago
(23-Aug-2026)
5/9 (55.56%)
$-8.79 (-9.37%)
25
Which stock is Kevin Fischbeck most bullish on?
Which stock is Kevin Fischbeck most reserved on?
What Year was the first public recommendation made by Kevin Fischbeck?